thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-05. Anything still debated is marked as such rather than presented as settled.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The United States Navy announced an operation by the same name in January 2025, using the Navy's Fourth Fleet, focused on integrating "robotic and autonomous systems with traditional naval forces". According to the Miami Herald, Foster Edwards, the 4th Fleet's Hybrid Fleet Director, "described Southern Spear as a significant step in the Navy's evolving Hybrid Fleet Campaign" that would "operationalize a heterogeneous mix of Robotic and Autonomous Systems to support the detection and monitoring of illicit trafficking while learning lessons for other theaters" and "help develop critical techniques and procedures for integrating RAS into the maritime environment." The Operation would use unmanned surface vessels supplied by Saildrone "to monitor illegal activity in the Caribbean and Pacific Ocean", according to Axios. Uncrewed boats for high-risk missions were being used to gather intelligence by June 2025. The United States Southern Command (USSOUTHCOM), whose area of responsibility covers Central and South America and the Caribbean, created a joint task force in October 2025 around the headquarters of II Marine Expeditionary Force (II MEF) tasked with "crushing" the drug cartels operating in the region. Later referred to as the Joint Task Force Southern Spear, its operations are coordinated with the 4th Fleet, the US Navy's component of USSOUTHCOM.
Vancomycin biosynthesis occurs primarily via three nonribosomal protein syntheses (NRPSs) VpsA, VpsB, and VpsC. The enzymes determine the amino acid sequence during its assembly through its 7 modules. Before vancomycin is assembled through NRPS, the non-proteinogenic amino acids are first synthesized. L-tyrosine is modified to become the β-hydroxytyrosine (β-HT) and 4-hydroxyphenylglycine (4-Hpg) residues. 3,5-dihydroxyphenylglycine ring (3,5-DPG) is derived from acetate.
== Structure == The MMPs have a common domain structure. The three common domains are the pro-peptide, the catalytic domain, and the haemopexin-like C-terminal domain, which is linked to the catalytic domain by a flexible hinge region.
=== Brand names === It is marketed under the brand name Rivotril by Roche in Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Canada, Colombia, Costa Rica, Croatia, the Czech Republic, Denmark, Estonia, Germany, Hungary, Iceland, Ireland, Italy, China, Mexico, the Netherlands, Norway, Portugal, Peru, Pakistan, Romania, Serbia, South Africa, South Korea, Saudi Arabia, Spain, Turkey, and the United States; Emcloz, Linotril, Lonazep, Clotrin and Clonotril in India and other parts of Europe; under the name Riklona in Indonesia and Malaysia; and under the brand name Klonopin by Roche in the United States. Other names, such as Antelepsin, Clonoten, Ravotril, Rivotril, Iktorivil, Clonex (Israel), Paxam, Petril, Naze, Zilepam and Kriadex, are used throughout the world. In August 2021, Roche Australia transferred Rivotril to Pharmaco Australia Ltd.
During Duterte's tenure as mayor, Davao City experienced economic boom and a significant decrease in crime from being a conflict-ridden area between communists and right-wing groups during the 1970s and 1980s, and is constantly rated as among the safest in the country. The city also ranks high in the world according to crowdsourced survey site Numbeo, a narrative that gained currency in the national media, creating a widespread public perception that has been a significant factor in establishing support for his nationwide drug policy. The city was also awarded "Most Child-Friendly City for Highly-Urbanized Category" in 1998, 1999, 2013 and 2014. Under Duterte's watch, the city council imposed a prohibition on selling, serving, drinking, and consuming alcoholic beverages from 01:00 until 08:00 each morning. Duterte signed Executive Order No. 39, reducing the speed limits for all kinds of motor vehicles within the territorial jurisdiction of Davao City in the interest of public safety and order. Duterte also signed Executive Order No. 04 creating the implementing of rules and regulations for a new comprehensive anti-smoking ordinance. A firecracker ban was also implemented by the City Council through the support of Duterte. Davao acquired 10 ambulances for central 911 intended for medical emergencies and 42 mobile patrol vehicles and motorcycles for the Davao City Police Office. Duterte, through Executive Order No.
Sources: en.wikipedia.org
There are concerns that some users may find it hard to stop using TikTok. Internal TikTok research has documented the addiction potential of the app. In April 2018, an addiction-reduction feature was added to Douyin. This encouraged users to take a break every 90 minutes. Later in 2018, the feature was rolled out to the TikTok app. TikTok uses popular influencers to encourage viewers to stop using the app and take a break. Many were also concerned with the app affecting users' attention spans due to the short-form nature of the content. This is a concern as many of TikTok's audience are younger children, whose brains are still developing. TikTok executives and representatives have noted and made aware to advertisers on the platform that users have poor attention spans. The company's survey reported that nearly 50% of social media users find it stressful to watch a video longer than a minute and a third of users watch videos at double speed. Their short attention spans posed a challenge for TikTok to pivot towards longer content formats. TikTok has also received criticism for enabling children to purchase coins which they can send to other users. Daily hours of entertainment screen media (Social Medias) may displace healthy behaviors such as socializing face to face, chores, hobbies, homework, family meals time, exercise, and sufficient sleep. Insomnia is considered a strong mediator between screen media time and mental health symptoms which implies that engaging in screen time pushes out adequate sleep and leads to decreased mental health.
=== Category:EC 3.5 (act on carbon–nitrogen bonds, other than peptide bonds) === Category:EC 3.5.1 (In linear amides) Urease (EC 3.5.1.5) Category:EC 3.5.2 (In cyclic amides) Beta-lactamase (EC 3.5.2.6) Category:EC 3.5.3 (In linear amidines) Arginase (EC 3.5.3.1) Category:EC 3.5.4 (In cyclic amidines) Adenosine deaminase (EC 3.5.4.4) GTP cyclohydrolase I (EC 3.5.4.16) Category:EC 3.5.5 (In nitriles) Nitrilase (EC 3.5.5.1)
=== Role in coagulation === Limulus clotting enzyme is part of the coagulation cascade in horseshoe crab hemocytes. The cascade is triggered by the presence of bacterial endotoxins, which are detected by Limulus clotting factor C. Factor C activates factor B, which activates the clotting enzyme. The clotting enzyme then activates coagulin. The coagulation cascade can also be triggered by (1,3)-β-D-glucan, a constituent of many fungal cell walls. The (1,3)-β-D-glucan-mediated cascade follows a different pathway than the endotoxin-mediated cascade. When (1,3)-β-D-glucan is present, Limulus factor G is activated. Factor G then activates the clotting enzyme, which proceeds to activate coagulin. Limulus clotting enzyme is inhibited by serpins LICI-2 and LICI-3. These serpins regulate the coagulation cascade by preventing diffusion of active clotting factors, which could lead to unnecessary clot formation. The horseshoe crab coagulation cascade is an important defense mechanism against bacterial and fungal invaders. Clots contain and immobilize infectious cells, which can then be killed with antimicrobial substances produced by the hemocytes. This specialized system is useful because invertebrates lack adaptive immunity.
== Structure == RTKs have a tripartite structure with extracellular, transmembrane, and cytoplasmic regions. This gene encodes a member of a novel subclass of RTKs and contains a distinct extracellular region encompassing a factor VIII–like domain.
Sources: en.wikipedia.org
In the absence of an effective enantiomeric environment (precursor, chiral catalyst, or kinetic resolution), separation of a racemic mixture into its enantiomeric components is impossible, although certain racemic mixtures spontaneously crystallize in the form of a racemic conglomerate, in which crystals of the enantiomers are physically segregated and may be separated mechanically. However, most racemates form crystals containing both enantiomers in a 1:1 ratio. In his pioneering work, Louis Pasteur was able to isolate the isomers of sodium ammonium tartrate because the individual enantiomers crystallize separately from solution. To be sure, equal amounts of the enantiomorphic crystals are produced, but the two kinds of crystals can be separated with tweezers. This behavior is unusual. A less common method is by enantiomer self-disproportionation. The second strategy is asymmetric synthesis: the use of various techniques to prepare the desired compound in high enantiomeric excess. Techniques encompassed include the use of chiral starting materials (chiral pool synthesis), the use of chiral auxiliaries and chiral catalysts, and the application of asymmetric induction. The use of enzymes (biocatalysis) may also produce the desired compound. A third strategy is enantioconvergent synthesis, the synthesis of one enantiomer from a racemic precursor, utilizing both enantiomers. By making use of a chiral catalyst, both enantiomers of the reactant result in a single enantiomer of product.
=== Generic names === Bicalutamide is the generic name of the drug in English and French and its INNTooltip INN, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, AANTooltip Australian Approved Name, and JANTooltip Japanese Accepted Name. It is also referred to as bicalutamidum in Latin, bicalutamida in Spanish and Portuguese, bicalutamid in German, and bikalutamid in Russian and other Slavic languages. The "bica-" prefix corresponds to the fact that bicalutamide is a bicyclic compound, while the "-lutamide" suffix is the standard suffix for NSAAs. Bicalutamide is also known by its former developmental code name ICI-176,334.
"In 1971 I stressed protein complementarity because I assumed that the only way to get enough protein ... was to create a protein as usable by the body as animal protein. In combating the myth that meat is the only way to get high-quality protein, I reinforced another myth. I gave the impression that in order to get enough protein without meat, considerable care was needed in choosing foods. Actually, it is much easier than I thought. "With three important exceptions, there is little danger of protein deficiency in a plant food diet. The exceptions are diets very heavily dependent on [1] fruit or on [2] some tubers, such as sweet potatoes or cassava, or on [3] junk food (refined flours, sugars, and fat). Fortunately, relatively few people in the world try to survive on diets in which these foods are virtually the sole source of calories. In all other diets, if people are getting enough calories, they are virtually certain of getting enough protein." The necessity of protein combining was not asserted. Rather, the increased biological value of meals where proteins are combined was noted. In a concession, Lappé removed from the second edition "charts that indicate exact proportions of complementary proteins". The American Dietetic Association reversed itself in its 1988 position paper on vegetarianism. Suzanne Havala, the primary author of the paper, recalls the research process:
The plans were bounced onto the Chief of Defence Staff, Field Marshal "Dwin" Bramall, over a weekend before publication on Monday, so senior officers had minimal time to drum up opposition in Parliament and the press. There was around three months of protest in the press, including from Bramall's predecessor Admiral of the Fleet Sir Henry Leach. Bramall obtained the concession that the individual service chiefs would be allowed to retain small staffs of their own and have a right of appeal to the prime minister. The changes took effect at the start of 1985. Bramall admired Heseltine's "great drive" and his "style, energy and vision about Europe", but was displeased at Heseltine's rudeness. It was not uncommon for Heseltine to summon him to a meeting early in the day, then keep Bramall "on hold" all day as he kept putting back the meeting, and eventually earning himself a rebuke for failing to display the respect with which every officer in the armed forces is trained to treat his subordinates. A number of senior officers spoke of Heseltine in scathing terms, for example for his self-centredness, to Michael Crick when he was researching his biography. Crick observes that with the exception of some defence chiefs, many people who worked with Heseltine came to "admire and respect him", although those who see him from afar are more suspect.
Recombinant human endostatin is a genetically engineered protein that interferes with the growth of blood vessels to a tumor, thereby starving and preventing the growth of tumor cells. Endu is a modified version of endostatin. Endu has been engineered to contain an additional nine-amino acid sequence to enhance protein purification, solubility and stability and has been shown to improve the function of endostatin. In June 2007, the company acquired an additional 10% equity interest in Yantai Medgenn. The company is conducting Phase IV clinical trials for Endu in approximately 150 hospitals in China.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.